|Organization Name||Columbia Tech Ventures|
|Institutional ID Number||10683|
|Technology Tags or Keywords|
Aldose reductase is an enzyme responsible for chronic diabetes related complications, such as retinopathy, neuropathy and nephropathy. This technology comprises of a family of molecules that act as aldose reductase inhibitors. In animal models, thes...
|Technology page URL||http://techventures.columbia.edu|
|Detailed Technology Description||
|TTO homepage URL||--|
|URL to link to documents, images, videos, etc.||--|
SummaryLead Inventors: Ann Marie Schmidt, Ravichandran Ramasamy, Ph.D., Andrew Wasmuth, Donald Landry, M.D., Ph.D.
Problem or Unmet Need:
Diabetes is one of the most common chronic disorders, affecting 1 in 12 individuals in US. Although rapid progress in drug development has transformed diabetes from a fatal to a manageable disorder, it has simultaneously resulted in an increased number of long-term complications. For example, cellular swelling is a chronic condition that previously would not have had time to manifest in diabetes patients. The current rise in long-term complications thus underscores the need for the development of new diabetes treatments.
Aldose reductase is an enzyme responsible for chronic diabetes related complications, such as retinopathy, neuropathy and nephropathy. This technology comprises of a family of molecules that act as aldose reductase inhibitors. In animal models, these inhibitors were effective at treating the many diabetes related complications. Additionally, the compounds have been shown to be useful for the treatment of cardiovascular complications and for improved wound healing outcomes.
Columbia Technology Ventures
Tel: (212) 854-8444